| scholarly article | Q13442814 |
| P50 | author | Caroline M. Apovian | Q54032792 |
| P2093 | author name string | Jennifer E Ho | |
| Alejandro Perez | |||
| Wilson S Colucci | |||
| Noyan Gokce | |||
| Deborah Siwik | |||
| Nir Ayalon | |||
| Yi-Chih Wang | |||
| Chang-Seng Liang | |||
| Vanessa Silva | |||
| Marcello Panagia | |||
| Deepa M Gopal | |||
| Aaron Sverdlov | |||
| Courtney Donohue | |||
| Jill Downing | |||
| Vijaya Kolachalama | |||
| P2860 | cites work | A new equation to estimate glomerular filtration rate | Q24651973 |
| 2013 ACCF/AHA guideline for the management of heart failure: executive summary: a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines | Q26864648 | ||
| Alterations of left ventricular myocardial characteristics associated with obesity. | Q51526288 | ||
| Pulmonary artery acceleration time provides an accurate estimate of systolic pulmonary arterial pressure during transthoracic echocardiography. | Q51576599 | ||
| RV Contractile Function and its Coupling to Pulmonary Circulation in Heart Failure With Preserved Ejection Fraction: Stratification of Clinical Phenotypes and Outcomes. | Q52680478 | ||
| Recommendations for chamber quantification: a report from the American Society of Echocardiography's Guidelines and Standards Committee and the Chamber Quantification Writing Group, developed in conjunction with the European Association of Echocardio | Q57217547 | ||
| Role of Biomarkers for the Prevention, Assessment, and Management of Heart Failure: A Scientific Statement From the American Heart Association | Q57629814 | ||
| Dimorphic cardiac adaptation to obesity and arterial hypertension | Q71124726 | ||
| Recommendations for cardiac chamber quantification by echocardiography in adults: an update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging | Q86455840 | ||
| Echocardiographic screening for non-ischaemic stage B heart failure in the community | Q88686818 | ||
| Using Biomarkers to Guide Heart Failure Therapy | Q89457614 | ||
| Obesity and the risk of heart failure | Q28216583 | ||
| Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement | Q29619465 | ||
| The origin of the "ideal" body weight equations | Q33917345 | ||
| Obesity and low-grade inflammation increase plasma follistatin-like 3 in humans | Q33930386 | ||
| Elevated pulmonary artery systolic pressure predicts heart failure admissions in African Americans: Jackson Heart Study. | Q33949881 | ||
| Guidelines for the echocardiographic assessment of the right heart in adults: a report from the American Society of Echocardiography endorsed by the European Association of Echocardiography, a registered branch of the European Society of Cardiology, | Q34125322 | ||
| Preclinical left ventricular diastolic dysfunction in metabolic syndrome. | Q34173271 | ||
| Progression of preclinical diastolic dysfunction to the development of symptoms | Q34294941 | ||
| Galectin-3 marks activated macrophages in failure-prone hypertrophied hearts and contributes to cardiac dysfunction | Q34364121 | ||
| Predictive value of plasma galectin-3 levels in heart failure with reduced and preserved ejection fraction | Q34528187 | ||
| Cardiac myocyte-specific ablation of follistatin-like 3 attenuates stress-induced myocardial hypertrophy | Q34684837 | ||
| The Natural History of Congestive Heart Failure: The Framingham Study | Q34701680 | ||
| Cardiac natriuretic peptides, obesity, and insulin resistance: evidence from two community-based studies | Q35432757 | ||
| FSTL3 deletion reveals roles for TGF-beta family ligands in glucose and fat homeostasis in adults | Q35611597 | ||
| Pulmonary pressures and death in heart failure: a community study | Q35673495 | ||
| Prevalence, clinical phenotype, and outcomes associated with normal B-type natriuretic peptide levels in heart failure with preserved ejection fraction | Q36203267 | ||
| Galectin-3, a marker of cardiac fibrosis, predicts incident heart failure in the community | Q36439679 | ||
| Relationship of plasma galectin-3 to renal function in patients with heart failure: effects of clinical status, pathophysiology of heart failure, and presence or absence of heart failure. | Q36522700 | ||
| Association of Borderline Pulmonary Hypertension With Mortality and Hospitalization in a Large Patient Cohort: Insights From the Veterans Affairs Clinical Assessment, Reporting, and Tracking Program. | Q36739428 | ||
| Pulmonary hypertension in heart failure with preserved ejection fraction: a community-based study | Q37328944 | ||
| Left ventricular hypertrophy patterns and incidence of heart failure with preserved versus reduced ejection fraction | Q37434977 | ||
| Left-ventricular hypertrophy and obesity: a systematic review and meta-analysis of echocardiographic studies | Q38169018 | ||
| Expression of follistatin-related genes is altered in heart failure | Q38289371 | ||
| Natriuretic peptide-based screening and collaborative care for heart failure: the STOP-HF randomized trial | Q38448978 | ||
| Assessing the Risk of Progression From Asymptomatic Left Ventricular Dysfunction to Overt Heart Failure: A Systematic Overview and Meta-Analysis | Q38673339 | ||
| Prevalence of Obesity Among Adults and Youth: United States, 2011-2014. | Q40246125 | ||
| Evidence Supporting the Existence of a Distinct Obese Phenotype of Heart Failure With Preserved Ejection Fraction | Q40256097 | ||
| Galectin-3 Participates in Cardiovascular Remodeling Associated With Obesity. | Q40560953 | ||
| Echocardiographic Pulmonary Artery Systolic Pressure in the Coronary Artery Risk Development in Young Adults (CARDIA) Study: Associations With Race and Metabolic Dysregulation. | Q41166063 | ||
| Follistatin-like 3 mediates paracrine fibroblast activation by cardiomyocytes | Q47232599 | ||
| Normalization for body size and population-attributable risk of left ventricular hypertrophy: the Strong Heart Study | Q47389566 | ||
| Relationship between obesity and B-type natriuretic peptide levels | Q47898393 | ||
| Systolic and diastolic heart failure in the community | Q48376632 | ||
| B-type natriuretic peptide strongly reflects diastolic wall stress in patients with chronic heart failure: comparison between systolic and diastolic heart failure | Q48644369 | ||
| Galectin-3 in patients with heart failure with preserved ejection fraction: results from the Aldo-DHF trial | Q48750580 | ||
| Recommendations for the Evaluation of Left Ventricular Diastolic Function by Echocardiography: An Update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging | Q49060993 | ||
| Metabolically Healthy Obese and Incident Cardiovascular Disease Events Among 3.5 Million Men and Women | Q50086254 | ||
| PONTIAC (NT-proBNP selected prevention of cardiac events in a population of diabetic patients without a history of cardiac disease): a prospective randomized controlled trial. | Q50869983 | ||
| Galectin-3 mediates the pulmonary arterial hypertension-induced right ventricular remodeling through interacting with NADPH oxidase 4. | Q51041161 | ||
| P433 | issue | 7 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | pulmonary hypertension | Q1128595 |
| P304 | page(s) | e011100 | |
| P577 | publication date | 2019-04-02 | |
| P1433 | published in | Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease | Q19880670 |
| P1476 | title | Galectin-3 Is Associated With Stage B Metabolic Heart Disease and Pulmonary Hypertension in Young Obese Patients | |
| P478 | volume | 8 |
| Q90073141 | Galectin-3 as a Next-Generation Biomarker for Detecting Early Stage of Various Diseases |
| Q92492024 | Galectin-3 as a candidate upstream biomarker for quantifying risks of myocardial ageing |
| Q100490766 | Galectin-3 is related to right ventricular dysfunction in heart failure patients with reduced ejection fraction and may affect exercise capacity |
Search more.